Abstract

Background

Literature with regard to coronavirus disease 2019 (COVID-19) associated morbidities and the risk factors for death are still emerging. In this study, we investigated the presence of kidney damage markers and their predictive value for survival among hospitalized subjects with COVID-19.

Methods

Forty-seven participants was included and grouped as: ‘COVID-19 patients before treatment’, ‘COVID-19 patients after treatment’, ‘COVID-19 patients under treatment in intensive care unit (ICU)’, and ‘controls’. Kidney function tests and several kidney injury biomarkers were compared between the groups. Cumulative rates of death from COVID-19 were determined using the Kaplan–Meier method. The associations between covariates including kidney injury markers and death from COVID-19 were examined, as well.

Results

Serum creatinine and cystatin C levels, urine Kidney Injury Molecule-1 (KIM-1)/creatinine ratio, and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), CKD-EPI cystatin C, and CKD-EPI creatinine–cystatin C levels demonstrated significant difference among the groups. The most significant difference was noted between the groups ‘COVID-19 patients before treatment’ and ‘COVID-19 patients under treatment in ICU’. Advancing age, proteinuria, elevated serum cystatin C, and urine KIM-1/creatinine ratio were all significant univariate correlates of death (p < 0.05, for all). However, only elevated urine KIM-1/creatinine ratio retained significance in an age, sex, and comorbidities adjusted multivariable Cox regression (OR 6.11; 95% CI: 1.22–30.53; p = 0.02), whereas serum cystatin C showing only a statistically non-significant trend (OR 1.42; 95% CI: 0.00–2.52; p = 0.09).

Conclusions

Our findings clearly demonstrated the acute kidney injury related to COVID-19. Moreover, urine KIM-1/creatinine ratio was associated with COVID-19 specific death.

Details

Title
Altered kidney function induced by SARS-CoV-2 infection and acute kidney damage markers predict survival outcomes of COVID-19 patients: a prospective pilot study
Author
Mustafa Zafer Temiz 1   VIAFID ORCID Logo  ; Ibrahim Hacibey 1   VIAFID ORCID Logo  ; Ramazan Omer Yazar 1   VIAFID ORCID Logo  ; Sevdi, Mehmet Salih 2   VIAFID ORCID Logo  ; Kucuk, Suat Hayri 3   VIAFID ORCID Logo  ; Alkurt, Gizem 4   VIAFID ORCID Logo  ; Doganay, Levent 4   VIAFID ORCID Logo  ; Doganay, Gizem Dinler 5   VIAFID ORCID Logo  ; Dincer, Muhammet Murat 1   VIAFID ORCID Logo  ; Yuruk, Emrah 6   VIAFID ORCID Logo  ; Erkalp, Kerem 2   VIAFID ORCID Logo  ; Muslumanoglu, Ahmet Yaser 1 

1  Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey 
2  Department of Anesthesiology and Reanimation, Bagcilar Training and Research Hospital, Istanbul, Turkey 
3  Department of Biochemistry, Bagcilar Training and Research Hospital, Istanbul, Turkey 
4  Genomic Laboratory (GLAB), Umraniye Training and Research Hospital, Elmalikent, Istanbul, Turkey 
5  Department of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey 
6  Department of Urology, BHT Clinic Istanbul Tema Hospital, Istanbul, Turkey 
Pages
233-240
Publication year
2022
Publication date
Dec 2022
Publisher
Taylor & Francis Ltd.
ISSN
0886022X
e-ISSN
15256049
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1080/0886022X.2022.2032743
ProQuest document ID
2780611489
Copyright
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons  Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.